Articles tagged "Heart transplant patients"

2018 American Transplant Congress
Outcomes of Subsequent Pregnancies in Female Heart Transplant Recipients
S. Rao,^1,2 D. Armenti,¹ L. Coscia,¹ S. Constantinescu,^1,2 M. Moritz.^1,3,4
¹Transplant Pregnancy Registry International, Gift of Life Institute, Philadelphia, PA; ²Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA; ³Surgery, Lehigh Valley Health Network, Allentown, PA; ⁴Surgery, Morsani College of Medicine, Tampa, FL.
The purpose of this study is to analyze the maternal and newborn outcomes in successive pregnancies in female heart transplant recipients (HT) reported to the…
2018 American Transplant Congress
The Renal Sparing Protocol after Heart Transplant That Keeps Giving
M. Kittleson, J. Patel, E. Kransdorf, S. Dimbil, R. Levine, D. Geft, D. Chang, L. Czer, R. Sharoff, J. Kobashigawa.
Cedars Sinai Medical Center, Los Angeles.
Purpose: Calcineurin inhibitors (CNI) such as cyclosporine and tacrolimus are known to cause chronic renal failure. As a result, programs have developed renal-sparing protocols (RSP)…
2018 American Transplant Congress
Solid Organ Transplantation and Data Mining: Risk Factors for Invasive Fungal Disease in Heart Transplant Recipients
N. Barros, D. Xie, C. Yek, T. Liu, X. Li, B. Adams-Huet, J. Martinez, S. Garg, J. Grodin, R. Morelend, A. Amin, F. Aras, J. Thibodeau, P. Mammen, M. Peltz, M. Drazner, W. Ring, R. Haley, R. La Hoz.
UT Southwestern, Dallas, TX.
We created a database of solid organ transplant (SOT) recipients using innovative data mining tools. This study describing the epidemiology of invasive fungal disease (IFD)…
2018 American Transplant Congress
Chronic Narcotic Use Increases Mortality Rates in Heart Transplantation
G. St. John, T. Chamogeorgakis, H. Nemeh, C. Tita, Y. Selektor, D. Lanfear, C. Williams.
Transplant, Henry Ford Hospital, Detroit, MI.
Purpose: In kidney and liver transplantation, chronic narcotic use pre and post-transplant has been associated with an increased risk for rejection and early graft loss.…
2018 American Transplant Congress
Deep Vein Thrombosis in Heart Transplant Patients
G. Bhat, T. Setia, C. Nguyen, I. Balanlayos, A-.G. Roska, A. Andrade, W. Cotts, G. Macaluso, S. Pauwaa, M. Bresticker, A. Tatooles, P. Pappas.
Heart Institute, Advocate Christ Medical Center, Oak Lawn, IL.
Introduction:Deep Vein Thrombosis (DVT) is one of the leading causes of cardiovascular morbidity and mortality. The incidence of DVT is usually higher in the lower…
2018 American Transplant Congress
Single-Cell Analysis of Graft Infiltrating T-Cells in Cardiac Allograft Vasculopathy
M. Habal, A. Myung, H. Yan, S. Rao, S. Lin, P. Colombo, C. Marboe, S. Restaino, A. Han, M. Farr, E. Zorn.
Medicine, Columbia University Medical Center, New York, NY.
Background: Cardiac allograft vasculopathy (CAV) remains a leading cause of death after heart transplant.T-cells are thought to play a central role, yet the mechanism by…
2018 American Transplant Congress
Air Pollution Can Support the Development of Cardiac Allograft Vasculopathy
C. Bara,¹ M. Barten,² D. Boethig,¹ Y. Scheibner,¹ J. Tauber,² H. Reichenspurner,² A. Haverich.¹
¹Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany; ²Cardiovascular Surgery, University Heart Center, Hamburg, Germany.
Purpose:Cardiac allograft vasculopathy (CAV) remains one of most important factors leading to graft dysfunction and mortality after heart transplantation (HTx). Thus, the identification of risk…
2018 American Transplant Congress
A Review of Pediatric Drug Development Programs and FDA Labeling for Immunosuppressive Drugs in Organ Transplant Patients
G. Burckart,¹ M. Cavaillé-Coll,² A. Duong,³ L. Hothem,⁴ R. Albrecht.²
¹Office of Clinical Pharmacology, Office of Translational Science, CDER, US Food and Drug Administration, Silver Spring, MD; ²Division of Transplant and Opthalmology Products, Office of New Drugs, CDER, US Food and Drug Administration, Silver Spring, MD; ³Tauro University, New York, NY; ⁴University of North Carolina, Chapel Hill, NC.
The development of drugs for organ transplantation spanned the time before and after pediatric regulatory requirements under the Best Pharmaceuticals for Children Act (BPCA) and…
2018 American Transplant Congress
Heart and Lung Transplantation Outcomes in HIV-Positive Recipients
C. Koval,¹ M. Malinis,² N. Mueller,³ J. Krisl,⁴ M. Hannan,⁵ P. Grossi,⁶ S. Huprikar.⁷
¹Infectious Diseases, Cleveland Clinic, Cleveland, OH; ²Infectious Diseases, Yale University, New Haven, CT; ³Infectious Diseases, University Hospital Zurich, Zurich, Switzerland; ⁴Pharmacy, Houston Methodist Hospital, Houston, TX; ⁵Infectious Diseases, Mater Hospital, Dublin, Ireland; ⁶Infectious Diseases, University Insubria, Varese, Italy; ⁷Infectious Diseases, Mount Sinai Hospital, New York, NY.
Purpose: Data for HIV+ patients receiving heart (HT) or lung transplantation (LT) are limited but appear to demonstrate acceptable outcomes. We aimed to add to…
2018 American Transplant Congress
Pre-Transplant Memory Patients Even without Detected Antibody Are at Rejection Risk in the First-Year after Heart Transplantation
J. Patel, M. Kittleson, E. Kransdorf, R. Levine, S. Dimbil, D. Geft, D. Chang, L. Czer, J. Kobashigawa.
Cedars Sinai Medical Center, Los Angeles.
Purpose: Patients (pts) with prior transplants, blood transfusions, and pregnancies awaiting heart transplantation (HTx) have potential to develop circulating anti-HLA antibodies (HLA Abs). Pts at…